import { EducationalContent } from '../../types';

export const pci: EducationalContent = {
  id: 'pci',
  type: 'concept',
  name: 'Percutaneous Coronary Intervention',
  nameEs: 'Intervencion Coronaria Percutanea',
  levels: {
    1: {
      level: 1,
      summary: 'Percutaneous coronary intervention (PCI) is a non-surgical procedure that uses a catheter with a small balloon and often a wire mesh tube (stent) to open blocked coronary arteries and restore blood flow to the heart.',
      explanation: 'Percutaneous coronary intervention, commonly known as PCI or angioplasty with stenting, is a minimally invasive procedure used to treat narrowed or blocked coronary arteries. Unlike bypass surgery, PCI does not require opening the chest. Instead, the procedure is performed through a small puncture in the wrist or groin.\n\nDuring PCI, a cardiologist threads a thin, flexible tube (catheter) through a blood vessel to the blocked coronary artery. A thin wire (guidewire) is carefully passed across the blockage. A small balloon on the tip of a catheter is then advanced over the wire to the site of the blockage and inflated. The inflated balloon pushes the plaque against the artery wall, widening the artery and restoring blood flow.\n\nIn most cases, a stent is placed during the procedure. A stent is a small expandable wire mesh tube that is mounted on the balloon catheter. When the balloon is inflated, the stent expands and locks into place against the artery wall, acting as a scaffold to keep the artery propped open after the balloon is deflated and removed. Over time, the artery lining grows over the stent, incorporating it into the vessel wall.\n\nThere are two main types of stents. Bare-metal stents (BMS) are plain metal mesh tubes. Drug-eluting stents (DES) are coated with medication that is slowly released to prevent the artery from narrowing again (a process called restenosis). Drug-eluting stents are used in the majority of PCI procedures today because they significantly reduce the chance of the artery re-narrowing compared to bare-metal stents.\n\nPCI is most commonly performed in two situations. In emergencies, it is the primary treatment for heart attacks (ST-elevation myocardial infarction or STEMI), where a coronary artery is suddenly and completely blocked by a blood clot. In these cases, rapid PCI (called primary PCI) can save heart muscle and lives. In non-emergency settings, PCI is performed to relieve symptoms of angina (chest pain) caused by significant coronary artery blockages when medications alone are not sufficient.\n\nAfter PCI with stent placement, patients must take blood-thinning medications (antiplatelet therapy), typically aspirin plus a second antiplatelet drug such as clopidogrel, prasugrel, or ticagrelor, for a specified period to prevent blood clots from forming inside the stent. The procedure typically takes 30 minutes to 2 hours, and most patients go home the next day.',
      keyTerms: [
        { term: 'PCI (Percutaneous Coronary Intervention)', definition: 'A catheter-based procedure that uses a balloon and usually a stent to open blocked coronary arteries without surgery' },
        { term: 'Stent', definition: 'A small expandable wire mesh tube permanently placed inside a coronary artery to keep it open after balloon angioplasty' },
        { term: 'Drug-eluting stent (DES)', definition: 'A stent coated with medication that slowly releases over time to prevent the treated artery from narrowing again' },
        { term: 'Angioplasty', definition: 'The use of a small balloon inflated inside a narrowed artery to widen it and improve blood flow' },
        { term: 'Antiplatelet therapy', definition: 'Blood-thinning medications taken after stent placement to prevent blood clots from forming inside the stent' }
      ],
      clinicalNotes: 'Primary PCI for STEMI should achieve door-to-balloon time of less than 90 minutes at PCI-capable hospitals. After DES placement, dual antiplatelet therapy (DAPT) with aspirin plus a P2Y12 inhibitor is required for a minimum of 6 months for stable disease and 12 months after acute coronary syndromes. Patients should be counseled about the critical importance of medication compliance; premature discontinuation of DAPT can lead to stent thrombosis, a life-threatening emergency.'
    },
    2: {
      level: 2,
      summary: 'PCI encompasses balloon angioplasty, bare-metal and drug-eluting stent implantation with current-generation platforms, and adjunctive pharmacotherapy including DAPT, guided by coronary angiography and physiologic assessment with FFR/iFR.',
      explanation: 'Percutaneous coronary intervention has evolved from simple balloon angioplasty to a sophisticated interventional platform incorporating advanced stent technology, intravascular imaging, physiologic assessment, and optimized antithrombotic regimens.\n\nThe evolution of stent technology spans several generations. First-generation drug-eluting stents (Cypher sirolimus-eluting, Taxus paclitaxel-eluting) dramatically reduced restenosis compared to bare-metal stents (from 20-30% to less than 10%) but were associated with late stent thrombosis due to delayed endothelialization. Second-generation DES (Xience everolimus-eluting, Resolute Integrity zotarolimus-eluting) use thinner struts (approximately 80 micrometers), more biocompatible polymers (fluoropolymer or bioabsorbable polymers), and improved anti-proliferative agents, resulting in lower rates of stent thrombosis and restenosis. Current third-generation platforms include ultra-thin strut designs (60 micrometers), fully bioabsorbable polymer coatings, and polymer-free drug-eluting stents. The ORSIRO and SYNERGY stents represent current state-of-the-art.\n\nProcedural technique involves arterial access (radial preferred), guide catheter engagement of the coronary ostium, lesion crossing with a guidewire, lesion preparation (predilation with a compliant or semi-compliant balloon), stent delivery and deployment at the appropriate inflation pressure (typically 12-16 atm), and post-dilation with a non-compliant balloon at high pressure to ensure optimal stent expansion. Adequate stent expansion is the single most important determinant of long-term outcomes.\n\nPhysiologic assessment using fractional flow reserve (FFR, abnormal less than 0.80) or instantaneous wave-free ratio (iFR, abnormal less than 0.89) should guide revascularization decisions for intermediate lesions (40-70% stenosis). The FAME trial demonstrated that FFR-guided PCI reduced major adverse cardiac events compared to angiography-guided PCI. Deferral of PCI for lesions with FFR greater than 0.80 is safe, as demonstrated in FAME 2 and DEFER trials.\n\nDual antiplatelet therapy (DAPT) is mandatory after PCI with stenting. Aspirin (81 mg daily, continued indefinitely) plus a P2Y12 receptor inhibitor forms the foundation. For acute coronary syndromes, more potent P2Y12 inhibitors (prasugrel or ticagrelor) are preferred over clopidogrel based on the TRITON-TIMI 38 and PLATO trials. DAPT duration is risk-stratified: 6 months minimum for stable coronary disease (may be shortened to 1-3 months in high bleeding risk patients with newer-generation DES), and 12 months for ACS (may be extended beyond 12 months in patients with high ischemic risk and low bleeding risk, based on DAPT score and PEGASUS-TIMI 54 trial). De-escalation strategies (switching from ticagrelor to clopidogrel at 1-3 months) are being investigated in the TWILIGHT and TICO trials.\n\nComplications of PCI include access site bleeding and hematoma, coronary dissection, abrupt vessel closure, no-reflow phenomenon (microvascular obstruction preventing adequate flow despite epicardial vessel patency), stent thrombosis (acute within 24 hours, subacute 1-30 days, late 30 days to 1 year, very late beyond 1 year), in-stent restenosis, contrast-induced nephropathy, and radiation injury.',
      keyTerms: [
        { term: 'Drug-eluting stent generations', definition: 'Progressive improvements in DES technology from first-generation (thick struts, durable polymers) through current ultra-thin strut platforms with bioabsorbable polymers and improved safety profiles' },
        { term: 'Fractional flow reserve (FFR)', definition: 'An invasive physiologic measurement of the hemodynamic significance of a coronary stenosis; values below 0.80 indicate ischemia-producing lesions that benefit from PCI' },
        { term: 'Dual antiplatelet therapy (DAPT)', definition: 'Combination of aspirin plus a P2Y12 inhibitor (clopidogrel, prasugrel, or ticagrelor) required after stent placement to prevent stent thrombosis' },
        { term: 'Stent thrombosis', definition: 'Formation of a blood clot inside a coronary stent causing sudden vessel occlusion; a rare but potentially fatal complication associated with premature DAPT discontinuation' },
        { term: 'No-reflow phenomenon', definition: 'Inadequate myocardial perfusion despite restored epicardial flow, caused by microvascular obstruction from distal embolization, vasospasm, or endothelial injury' },
        { term: 'In-stent restenosis', definition: 'Renarrowing of a stented coronary artery from neointimal hyperplasia, occurring in less than 10% with current-generation DES' }
      ],
      clinicalNotes: 'Radial access should be the default approach (CLASS I recommendation) due to reduced bleeding, improved patient comfort, and mortality benefit in ACS. Loading doses of antiplatelet therapy should be administered as early as possible: aspirin 325 mg and P2Y12 inhibitor loading dose (clopidogrel 600 mg, prasugrel 60 mg, or ticagrelor 180 mg). Avoid prasugrel in patients over 75, less than 60 kg, or with prior stroke/TIA. For primary PCI in STEMI, thrombus aspiration is no longer routinely recommended (TOTAL trial). Adequate hydration and minimizing contrast volume reduce contrast-induced nephropathy risk.'
    },
    3: {
      level: 3,
      summary: 'Advanced PCI includes intravascular imaging-guided optimization, complex bifurcation and left main stenting techniques, chronic total occlusion intervention, atherectomy devices, and risk-stratified antithrombotic strategies with DAPT optimization algorithms.',
      explanation: 'Advanced PCI addresses complex coronary anatomy and clinical scenarios requiring specialized techniques, intravascular imaging guidance, and individualized antithrombotic management.\n\nIntravascular imaging optimization using IVUS or OCT significantly improves PCI outcomes. IVUS provides deep tissue penetration for accurate vessel sizing, identification of external elastic membrane dimensions, and assessment of stent expansion relative to reference vessel size. Minimum stent area (MSA) is the strongest predictor of stent failure; targets include MSA greater than 5.5 mm2 for non-left main stents and greater than 8.0 mm2 for left main stents. OCT offers superior resolution (10-20 micrometers) for identifying edge dissections, tissue prolapse, malapposition, and incomplete stent strut coverage. The ILUMIEN IV trial demonstrated that OCT-guided PCI achieved larger minimum stent area than angiography-guided PCI, and the OCTOBER trial showed reduced major cardiac events with OCT guidance in complex bifurcation PCI.\n\nBifurcation PCI involves the treatment of lesions at coronary branch points. The provisional single-stent strategy (stenting the main branch only, with side branch intervention only if needed) is the preferred approach for most bifurcations, based on evidence from the EBC MAIN, DK CRUSH, and DEFINITION trials. However, complex bifurcations involving large side branches with ostial disease may benefit from two-stent techniques: Culotte (overlapping stents with sequential rewiring and kissing balloon inflation), crush or double-kissing crush (DK-crush, stenting the side branch first then crushing with the main branch stent), and T-stenting. Final kissing balloon inflation and POT (proximal optimization technique) are essential steps for all two-stent techniques.\n\nLeft main PCI has emerged as an alternative to CABG for selected patients with unprotected left main disease. The EXCEL and NOBLE trials compared left main PCI with DES versus CABG. Patient selection favors PCI for low-to-intermediate SYNTAX scores (less than 33) and simpler distal left main bifurcation anatomy. Left main PCI requires IVUS optimization with target stent expansion greater than or equal to 80% of reference in the polygon of confluence, proximal optimization technique, and meticulous attention to side branch access. The single crossover stenting technique from the left main into the LAD with provisional stenting of the circumflex is preferred.\n\nChronic total occlusion (CTO) PCI involves recanalization of a completely occluded coronary artery present for at least 3 months. CTO-PCI is one of the most technically demanding procedures in interventional cardiology with success rates of 80-90% in experienced hands. Modern CTO-PCI employs multiple crossing strategies: antegrade wire escalation (sequential use of progressively stiffer wires), antegrade dissection and re-entry (ADR, using the Stingray system to create a subintimal channel and re-enter the true lumen), and retrograde approaches (accessing the CTO from the distal cap via collateral channels, using retrograde wire crossing or controlled antegrade and retrograde subintimal tracking, CART). The hybrid algorithm developed by the Hybrid CTO Operators group provides a systematic framework for strategy selection based on lesion characteristics.\n\nAther ectomy devices address heavily calcified lesions that resist balloon dilation and prevent adequate stent expansion. Rotational atherectomy (Rotablator) uses a diamond-tipped burr rotating at 135,000-180,000 RPM to ablate superficial calcium. Orbital atherectomy (Diamondback 360) uses an eccentrically mounted diamond-coated crown that orbits the vessel wall, creating a larger lumen than its resting crown diameter. Intravascular lithotripsy (Shockwave) delivers sonic pressure waves through a balloon catheter that fracture intimal and medial calcium while preserving soft tissue. Excimer laser coronary atherectomy (ELCA) uses ultraviolet light to ablate tissue and is used for in-stent restenosis, underexpanded stents, and fibrotic lesions.\n\nDAPT optimization uses clinical decision tools including the DAPT score (integrating age, diabetes, smoking, prior PCI/MI, paclitaxel-eluting stent, stent diameter, CHF/LVEF, and vein graft stent) and the PRECISE-DAPT score (bleeding risk score using age, creatinine clearance, hemoglobin, white blood cell count, and prior bleeding). High DAPT score (greater than or equal to 2) favors extended DAPT beyond 12 months, while high PRECISE-DAPT score (greater than or equal to 25) favors shortened DAPT. The ARC-HBR criteria define high bleeding risk patients who may benefit from abbreviated 1-3 month DAPT with current-generation DES.',
      keyTerms: [
        { term: 'Minimum stent area (MSA)', definition: 'The smallest cross-sectional area within a deployed stent measured by IVUS or OCT; the most powerful predictor of stent thrombosis and restenosis' },
        { term: 'Chronic total occlusion (CTO)', definition: 'A completely occluded coronary artery of at least 3 months duration, requiring specialized crossing techniques including antegrade, retrograde, and dissection-reentry approaches' },
        { term: 'Intravascular lithotripsy', definition: 'A calcium modification technique using sonic pressure waves delivered through a balloon catheter to fracture calcified plaque without damaging soft tissue' },
        { term: 'Provisional bifurcation strategy', definition: 'The preferred approach for most coronary bifurcation lesions, stenting only the main branch and intervening on the side branch only if flow is compromised' },
        { term: 'Proximal optimization technique (POT)', definition: 'Inflation of a short non-compliant balloon in the proximal stent segment at the bifurcation carina to optimize stent geometry and facilitate side branch access' },
        { term: 'DAPT score', definition: 'A clinical decision tool integrating patient and procedural factors to estimate the benefit-risk balance of extended dual antiplatelet therapy beyond 12 months' }
      ],
      clinicalNotes: 'IVUS should be used for all left main PCI and strongly considered for complex PCI including bifurcations, CTOs, long lesions, and in-stent restenosis. Target MSA greater than 80% of the distal reference vessel area. For CTO-PCI, operator volume (greater than 50 CTOs/year) is the strongest predictor of success; refer complex cases to dedicated CTO programs. Intravascular lithotripsy is preferred over rotational atherectomy for severe calcification due to its ease of use and lower complication rate. Patients on oral anticoagulants (warfarin, DOACs) undergoing PCI require careful antiplatelet management: typically triple therapy (OAC + aspirin + P2Y12 inhibitor) for 1 week to 1 month, followed by dual therapy (OAC + P2Y12 inhibitor) for up to 12 months.'
    },
    4: {
      level: 4,
      summary: 'Complex PCI scenarios include mechanical circulatory support-assisted high-risk procedures, bioresorbable vascular scaffolds, drug-coated balloons for in-stent restenosis and small vessels, coronary physiology-guided complete revascularization strategies, and management of acute coronary syndromes with multi-vessel disease.',
      explanation: 'Expert PCI practice addresses the highest-risk patients and most complex lesion subsets, integrating hemodynamic support devices, advanced imaging, and evolving evidence for complete revascularization strategies.\n\nHigh-risk PCI with mechanical circulatory support (MCS) is indicated for patients with complex anatomy, severely reduced ventricular function, or unprotected left main disease in whom hemodynamic compromise during intervention is anticipated. The Impella CP provides up to 3.7 L/min of forward flow via a micro-axial pump placed retrograde across the aortic valve. The PROTECT III trial is evaluating outcomes of Impella-supported versus non-supported high-risk PCI. Patient selection for MCS-assisted PCI considers the SCAI-CHIP (complex, high-risk, indicated patient) criteria including LVEF less than 35%, unprotected left main disease, last remaining conduit intervention, and severe aortic stenosis with PCI. The TandemHeart and VA-ECMO provide alternative support options for the most hemodynamically tenuous patients.\n\nBioresorbable vascular scaffolds (BVS) were designed to provide temporary vessel support during healing and then dissolve, restoring vasomotion and eliminating permanent metallic implant-related complications. The Absorb BVS (Abbott) was the first commercially available scaffold but was withdrawn from the market after the ABSORB III trial demonstrated higher rates of scaffold thrombosis and target vessel MI compared to metallic DES, attributed to thick struts (157 micrometers), slow resorption kinetics, and late scaffold discontinuity. Next-generation BVS with thinner struts, faster resorption, and improved radial strength (Magmaris sirolimus-eluting magnesium scaffold, DESolve novolimus-eluting PLLA scaffold) are under active investigation with more promising early results.\n\nDrug-coated balloons (DCB) deliver antiproliferative drug (paclitaxel or sirolimus) to the vessel wall without leaving a permanent implant. DCB are the preferred treatment for in-stent restenosis (Class I recommendation), demonstrating superiority over both plain balloon angioplasty and repeat DES implantation in the ISAR-DESIRE 3 trial. DCB are also being investigated for de novo small-vessel disease (less than 2.5 mm reference diameter), where DES implantation carries higher restenosis risk. The BASKET-SMALL 2 trial demonstrated non-inferiority of DCB versus DES for small-vessel disease. Sirolimus-coated balloons (Magic Touch, Selution SLR) represent an emerging technology with potentially superior efficacy over paclitaxel-coated balloons.\n\nComplete revascularization in STEMI with multi-vessel disease has evolved significantly. Traditional teaching recommended treating only the culprit lesion during primary PCI. However, the COMPLETE, COMPARE-ACUTE, and CvLPRIT trials demonstrated that complete revascularization of significant non-culprit lesions (either staged during index hospitalization or at a subsequent procedure) reduces the composite of cardiovascular death and MI compared to culprit-only PCI. FFR-guided complete revascularization during the index admission is now recommended (Class I, 2021 ACC/AHA guidelines) for STEMI patients with multi-vessel disease and hemodynamic stability.\n\nCardiogenic shock with multi-vessel disease presents the most challenging PCI scenario. The CULPRIT-SHOCK trial demonstrated that a culprit-lesion-only strategy with potential for staged revascularization reduced 30-day mortality and renal replacement therapy compared to immediate multi-vessel PCI in patients with cardiogenic shock. This counterintuitive result is attributed to contrast volume reduction, shorter procedure times, and avoidance of hemodynamic compromise from non-culprit interventions during acute shock.\n\nCoronary artery perforation is a feared complication of aggressive lesion preparation (atherectomy, high-pressure ballooning). Management depends on perforation severity: Type I (extraluminal crater without extravasation) requires observation; Type II (myocardial or pericardial staining) requires prolonged balloon inflation and observation; Type III (frank extravasation greater than 1 mm, cavity spilling) requires immediate prolonged balloon tamponade, covered stent deployment, reversal of anticoagulation with protamine, and pericardiocentesis for tamponade. Emergency cardiac surgery should be available as a backup.',
      keyTerms: [
        { term: 'High-risk PCI with MCS', definition: 'Percutaneous coronary intervention in hemodynamically vulnerable patients supported by mechanical circulatory support devices (Impella, TandemHeart, ECMO) to maintain systemic perfusion' },
        { term: 'Bioresorbable vascular scaffold', definition: 'A temporary coronary scaffold that provides mechanical support during healing and then dissolves, with the goal of restoring native vessel physiology' },
        { term: 'Drug-coated balloon', definition: 'A balloon catheter coated with antiproliferative drug that is transferred to the vessel wall during inflation, treating disease without leaving a permanent implant' },
        { term: 'Complete revascularization in STEMI', definition: 'Treatment of all significant coronary stenoses (not just the culprit lesion) in STEMI patients with multi-vessel disease, shown to improve outcomes in the COMPLETE trial' },
        { term: 'Coronary perforation', definition: 'A procedural complication where the coronary vessel wall is disrupted, potentially causing pericardial effusion and tamponade; classified by Ellis Perforation Classification' },
        { term: 'Covered stent', definition: 'A stent with a membrane covering (PTFE) used to seal coronary perforations and exclude pseudoaneurysms' }
      ],
      clinicalNotes: 'MCS-assisted PCI should be considered when the myocardium at jeopardy exceeds 50% of the total myocardium (based on coronary anatomy and collateral supply) combined with LVEF less than 30%. Bioresorbable scaffolds should only be used within clinical trials until next-generation devices demonstrate improved safety. For in-stent restenosis, DCB is preferred over repeat DES for DES-ISR, while DES is preferred for BMS-ISR. In cardiogenic shock with multi-vessel disease, follow the CULPRIT-SHOCK strategy: culprit-only PCI during the index procedure with staged non-culprit PCI after hemodynamic stabilization.'
    },
    5: {
      level: 5,
      summary: 'Frontier PCI encompasses robotic-assisted coronary intervention, AI-guided procedural decision support, sirolimus-eluting bioresorbable scaffolds, coronary gene therapy delivered during PCI, and precision antiplatelet therapy guided by pharmacogenomics and platelet function testing.',
      explanation: 'The frontier of percutaneous coronary intervention integrates robotics, artificial intelligence, next-generation biomaterials, and personalized pharmacotherapy to advance both procedural technique and long-term outcomes.\n\nRobotic-assisted PCI using the Corindus CorPath GRX system enables remote manipulation of guidewires, balloons, and stent delivery catheters from a radiation-shielded cockpit. Robotic PCI reduces operator radiation exposure by over 95% and enables sub-millimeter precision in device positioning. The R-EVOLUTION study demonstrated feasibility and safety of robotic PCI for complex lesions. Teleoperated PCI (performing procedures from a remote location) has been demonstrated in proof-of-concept studies and may eventually enable expert operators to treat patients at facilities without on-site interventional cardiology coverage. AI integration with robotic platforms could enable semi-autonomous stent positioning based on real-time intravascular imaging analysis.\n\nAI-guided PCI decision support encompasses multiple applications: (1) Automated angiographic analysis using deep learning to quantify stenosis severity, assess lesion characteristics (calcification, length, bifurcation involvement), and predict procedural success. (2) Real-time OCT analysis with automatic identification of calcium arc, lumen dimensions, plaque composition, and optimal stent landing zones. (3) Predictive modeling for in-stent restenosis and stent thrombosis risk based on patient, lesion, and procedural variables. (4) Computational simulation of stent deployment biomechanics to predict optimal sizing, positioning, and post-dilation strategy. The SYNTAX AI study demonstrated that machine learning can replicate the SYNTAX score calculation with high accuracy, and AI-augmented FFR calculation from angiographic images (QFR, vessel FFR) may eventually replace invasive physiologic assessment.\n\nNext-generation bioresorbable scaffolds address the limitations of first-generation devices. Magnesium-based scaffolds (Magmaris, Biotronik) resorb within 12 months (versus 3 years for PLLA), provide superior radial strength, and have thinner struts (approximately 150 micrometers). Sirolimus-eluting bioresorbable scaffolds (Fantom Encore, DESolve Cx) use newer polymers with optimized degradation profiles. Iron-based bioresorbable scaffolds combine the strength of metal with complete bioresorption over 1-2 years. Polymer-free technology combining drug micro-reservoirs with bioresorbable metallic scaffolds may represent the optimal solution. The key challenge remains achieving the deliverability and radial strength of metallic DES while providing complete bioresorption.\n\nCoronary drug delivery beyond stents and balloons is an expanding field. Micro-needle delivery catheters (Bullfrog, Mercator MedSystems) enable direct injection of therapeutics into the adventitia of coronary arteries during PCI. Applications include delivery of anti-inflammatory agents (dexamethasone), gene therapy vectors, and anti-proliferative biologics to the vessel wall for targeted treatment of vulnerable plaque or restenosis prevention. Nanoparticle-based drug delivery systems targeting inflamed endothelium may enable systemic administration of plaque-stabilizing agents with coronary tropism.\n\nPrecision antiplatelet therapy aims to individualize P2Y12 inhibitor selection based on pharmacogenomic testing and platelet function assays. CYP2C19 loss-of-function alleles (primarily CYP2C19*2 and *3) affect clopidogrel metabolism, resulting in reduced active metabolite generation and higher rates of stent thrombosis. The TAILOR-PCI trial evaluated genotype-guided antiplatelet therapy, and while it did not demonstrate a statistically significant overall benefit, subgroup analysis suggested benefit in high-risk patients. Platelet function testing using the VerifyNow P2Y12 assay or vasodilator-stimulated phosphoprotein (VASP) assay can identify clopidogrel non-responders who may benefit from switching to a more potent agent. The integration of genetic testing, platelet function assessment, and clinical risk scores may enable truly personalized antiplatelet strategies that optimize the balance between ischemic protection and bleeding risk.\n\nThe convergence of AI-driven procedural guidance, next-generation biomaterials, targeted drug delivery, and pharmacogenomic-guided therapy is creating a future where PCI is not merely a mechanical procedure to prop open arteries but a comprehensive vascular therapeutic intervention that addresses the biological basis of coronary artery disease at the molecular level.',
      keyTerms: [
        { term: 'Robotic-assisted PCI', definition: 'Remote-controlled coronary intervention using robotic platforms that enable precise device manipulation while dramatically reducing operator radiation exposure' },
        { term: 'AI-guided PCI', definition: 'Artificial intelligence applications providing real-time decision support during PCI including automated stenosis quantification, optimal stent sizing, and intravascular image interpretation' },
        { term: 'Magnesium bioresorbable scaffold', definition: 'A next-generation bioresorbable coronary scaffold using magnesium alloy that provides rapid (12-month) complete resorption with improved radial strength compared to polymer-based scaffolds' },
        { term: 'Coronary micro-needle delivery', definition: 'Catheter-based injection of therapeutics directly into the coronary vessel wall adventitia during PCI for targeted local drug, gene, or biologic therapy' },
        { term: 'CYP2C19 pharmacogenomics', definition: 'Genetic testing for loss-of-function alleles affecting clopidogrel metabolism, identifying patients who may benefit from alternative antiplatelet agents due to impaired drug activation' },
        { term: 'Nanoparticle drug delivery', definition: 'Engineered nanoscale carriers targeting inflamed coronary endothelium for systemic delivery of plaque-stabilizing or anti-restenotic therapies with coronary specificity' }
      ],
      clinicalNotes: 'Robotic PCI is most beneficial for operators performing high-volume PCI with cumulative radiation exposure concerns. Current limitations include inability to perform manual thrombectomy and limited tactile feedback. AI-assisted angiographic analysis tools are entering clinical practice but should be used as decision support, not autonomous decision-makers. Bioresorbable scaffolds remain investigational in most markets; enrollment in clinical trials is recommended for interested patients. CYP2C19 genotyping is increasingly available and should be considered for patients undergoing PCI who will receive clopidogrel, particularly those with ACS or high-risk anatomy. Point-of-care genotyping with turnaround times of 1-2 hours is now feasible in the catheterization laboratory.'
    }
  },
  media: [],
  citations: [
    { id: 'pci-c1', source: 'Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization. Circulation. 2022;145(3):e18-e114.', url: 'https://doi.org/10.1161/CIR.0000000000001038' },
    { id: 'pci-c2', source: 'Mehran R, Baber U, Sharma SK, et al. Ticagrelor with or without Aspirin in High-Risk Patients after PCI (TWILIGHT). N Engl J Med. 2019;381(21):2032-2042.', url: 'https://doi.org/10.1056/NEJMoa1908419' },
    { id: 'pci-c3', source: 'Mehta SR, Wood DA, Storey RF, et al. Complete Revascularization with Multivessel PCI for Myocardial Infarction (COMPLETE). N Engl J Med. 2019;381(15):1411-1421.', url: 'https://doi.org/10.1056/NEJMoa1907775' }
  ],
  crossReferences: [
    { contentId: 'cabg', relationship: 'related', description: 'CABG is the surgical alternative to PCI for coronary revascularization, with selection guided by anatomy and patient factors' },
    { contentId: 'cardiaccath', relationship: 'related', description: 'Diagnostic cardiac catheterization defines coronary anatomy and guides PCI decision-making' },
    { contentId: 'stresstest', relationship: 'related', description: 'Stress testing identifies ischemia that may lead to catheterization and PCI' }
  ],
  tags: {
    defined: ['interventional-cardiology', 'PCI', 'stenting', 'coronary-revascularization', 'acute-coronary-syndrome', 'STEMI'],
    generated: ['drug-eluting-stent', 'DAPT', 'bifurcation-PCI', 'CTO', 'intravascular-imaging', 'FFR']
  },
  createdAt: '2025-01-25',
  updatedAt: '2025-01-25',
  version: 2,
  status: 'published'
};
